Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Sunesis Pharmaceuticals
company
About
Sunesis Pharmaceuticals is focused on the R&D of oncology therapeutics for the treatment of solid and hematologic cancers.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $43.50M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Sunesis is an emerging biopharmaceutical company creating new medicines to improve the lives of people with cancer. They are building a pipeline of drugs that selectively block critical mechanisms required for tumor growth and survival. The fight against cancer is an enormous mission that requires an integrated approach fueled by a commitment to innovation.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$43.50M
Sunesis Pharmaceuticals has raised a total of
$43.50M
in funding over 2 rounds. Their latest funding was raised on
Apr 7, 2009 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 7, 2009 | Post-IPO Equity | $43.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Sunesis Pharmaceuticals is funded by 1 investors.
Caxton Advantage Life Sciences Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Caxton Advantage Life Sciences Fund
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
